2 registrations that name BPC-157 as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 2 registrations
Read closelyRecruitingNCT07437547
BPC 157 for Acute Hamstring Muscle Strain Repair
Phase 2
Hudson Biotech
About 120 people
Started Feb 2, 2026
In plain words A Phase 2 study of BPC-157 in people 18 to 45, run by Hudson Biotech. It plans to enroll about 120 people at 1 site, none in the US.
It lists one site, in China, and no US site.
The same sponsor, Hudson Biotech, registered a tesamorelin study titled “Mock Study” (NCT07481734).
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 45. Conditions: Hamstring Muscle Strain; Skeletal Muscle Injury.
Age 18 to 45 years.
Acute posterior thigh pain consistent with hamstring strain with onset within 72 hours prior to screening.
MRI-confirmed grade II hamstring strain of the biceps femoris, semitendinosus, or semimembranosus, with measurable lesion.
Pre-injury physical activity >= 3 sessions/week or participation in organized recreational sport.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Pentadecapeptide BPC 157; Placebo
Registered summary
This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07803250
Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery
Phase 1
University of Arkansas
About 30 people
Starts Jan 1, 2027 (estimated)
In plain words A Phase 1 study of BPC-157 in people 18 and older, run by University of Arkansas. It plans to enroll about 30 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Rotator Cuff Tear.
Males and Females, 18 years old or older
Body mass index of 20.0 to 34.9 kg/m2
Pre-operative MRI demonstrating a full thickness tear of the posterosuperior rotator cuff less than 2.5 cm in anteroposterior dimension
Scheduled for an aRCR at UAMS with Dr. Ryan Hill, Dr. Paul Inclan, or Dr. Justin Rabinowitz
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
BPC-157; Sham (No Treatment)
Registered summary
This study is a randomized, double-blind, placebo-controlled pilot trial investigating the effects of BPC-157 on tendon healing and functional recovery following arthroscopic rotator cuff repair (aRCR). BPC-157 is a synthetic peptide that has demonstrated promising regenerative and anti-inflammatory effects in preclinical animal models of musculoskeletal injury, but it has not yet been studied in formal human clinical trials. Twenty patients undergoing aRCR will be enrolled and randomly assigned to receive either BPC-157 or a saline placebo. The full summary is on the listing.